Skip to content
Medical Health Aged Care, Mental Health

Monash University Expert: World Mental Health Day, 10 October 2023

Monash University 2 mins read

This year the theme for World Mental Health Day is ‘mental health is a universal right’. An expert in medical treatments for mental health conditions from Monash University is available for comment.

Professor Chris Langmead, Director of the Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences
Contact: M: +61 (0)417 959083 / E: [email protected] 

  • There have been no new medicines to treat mental health conditions for 50+ years - in order to make real change to the overall quality of life for patients, this must change.     

  • Limited resources/funding invested into research for the discovery and development of novel medicines to treat mental health conditions has hindered progress. 

  • Accessibility is key - when new medicines (including treatments such as psychedelic-assisted therapy) become an option, they must be rigorously assessed from an economic perspective to ensure they are not reserved to only a small number of patients who can afford them. 

The following quotes can be attributed to Professor Langmead:

“Mental health is a basic human right for everyone, yet one in eight people globally are living with a mental health condition. We need new drugs that are safe and more effective than current options, particularly for difficult to treat mental health conditions. But they also need to be affordable for everyone in need, not just small cohorts of the population.

“Since the 1970s there have been extraordinary breakthroughs in medical treatments for many diseases like cancer, diabetes, heart disease and dementia. Yet new medicines to treat mental health conditions have remained stagnant, due in part to limited resources and funding.

“Recently Australia’s Therapeutic Goods Administration (TGA) approved the use of MDMA and psilocybin for the treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression, respectively. This has opened up really exciting new opportunities for Australia, however there are still major issues to tackle in order for the TGA’s reclassification to benefit those most in need.


Contact details:

Kate Carthew

+61 438 674 814

[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 17/04/2026
  • 08:05
Royal Australian College of GPs

New specialist GPs to be welcomed at Fellowship ceremony in Cairns

The Royal Australian College of GPs (RACGP) is celebrating new Fellows at a ceremony in Cairns this week, marking their entry into the profession as specialist GPs.  The RACGP Queensland Faculty will host its annual regional Fellowship ceremony on Friday 17 April, welcoming 27 new Fellows to the profession.  Fellowship of the RACGP (FRACGP) reflects a doctor’s qualification and expertise as a specialist GP, following around 11 years of education, training, rigorous assessment, and experience in primary care.  This event marks an ongoing commitment by the RACGP Queensland Faculty to hold a Fellowship ceremony in a regional area annually. The ceremony was last held in Cairns in 2021.  RACGP President Dr Michael Wright congratulated the…

  • Finance Investment, Medical Health Aged Care
  • 16/04/2026
  • 15:21
JMM

BlinkLab Secures A$17.5M to Advance FDA Trial and Commercial Launch of AI-Powered Autism Diagnostic, Expands ADHD Program

BlinkLab Limited (ASX: BB1) a digital healthcare company developing AI-powered diagnostic technologies, has secured A$17.5 million in an oversubscribed placement to institutional and sophisticated investors, positioning the Company to accelerate regulatory milestones and commercialisation of its lead autism diagnostic platform while expanding into the significantly larger ADHD market. The capital raise, priced at A$0.65 per share, marks a critical inflection point for BlinkLab as it advances toward FDA approval and market entry for BlinkLab Dx1, its smartphone-based diagnostic aid for autism. Funding to Accelerate Regulatory Pathway and Commercial Readiness Proceeds from the placement will be deployed across key value-driving initiatives,…

  • Contains:
  • Medical Health Aged Care
  • 16/04/2026
  • 15:11
Galderma

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+(TM), Powered by Its Next-Generation TriHex Technology® Regenerative Platform

Regenerating Skin Nectar has long played a central role in the peri-procedural skin journey as part of Alastin’s dedicated procedure support portfolio, enhancing the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.